Adding Hormone Therapy to Postoperative Radiotherapy Confers a Survival Benefit in Patients With Prostate Cancer and High PSA

Default Digital Object Group 2026 Dataset

View at publisher
DOI: 10.1200/adn.26.300355
Cited by: 0

Abstract

Results from the POSEIDON meta-analysis of 6 phase 3 randomized trials show no meaningful OS benefit with the addition of hormone therapy to postoperative radiotherapy in patients with recurrent prostate cancer (Abstract 305). However, additional analysis of the interaction effect revealed a survival benefit in a subgroup of patients with a high PSA level (> 0.5 ng/mL).

Fields of Study & Subjects

Prostate Cancer Diagnosis and Treatment Prostate Cancer Treatment and Research Breast Cancer Treatment Studies

Publication details

Journal / source
Default Digital Object Group
Publication date
26 February 2026
Language
EN
Document type
Dataset